GeneDx Hldgs Q2 Adj EPS $(1.65) Misses $(1.31) Estimate, Sales $48.71M Beat $47.63M Estimate
Portfolio Pulse from vinayak@benzinga.com
GeneDx Hldgs (NASDAQ:WGS) reported Q2 losses of $(1.65) per share, missing the analyst consensus estimate of $(1.31) by 25.95%. However, the company's quarterly sales of $48.71 million beat the estimate of $47.63 million by 2.26%. This represents a 34.66% increase over sales from the same period last year.
August 08, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GeneDx Hldgs reported a larger than expected Q2 loss but beat sales estimates. This mixed result could lead to volatility in the stock's price.
GeneDx Hldgs reported a larger than expected loss for Q2, which is negative for the stock. However, the company beat sales estimates, which is positive. These mixed results could lead to uncertainty and volatility in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100